Illumina Unveils Strategy to Enter Molecular Diagnostics Market

CEO Jay Flatley told the JPMorgan Healthcare Conference in San Francisco last week that the company will be investing in developing new and improving existing sequencing technologies to enter into the $3 billion molecular diagnostics space.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories